Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Pasi Pennanen"'
Autor:
Reetta Nätkin, Pasi Pennanen, Heimo Syvälä, Merja Bläuer, Juha Kesseli, Teuvo L J Tammela, Matti Nykter, Teemu J Murtola
Publikováno v:
PLoS ONE, Vol 18, Iss 2, p e0281645 (2023)
Androgen deprivation therapy is the cornerstone treatment of advanced prostate cancer. Eventually prostate cancer cells overcome androgen deprivation therapy, giving rise to castration resistant prostate cancer (CRPC) characterized by increased andro
Externí odkaz:
https://doaj.org/article/9203e67f881845b9a88f84cbfa676d4a
Autor:
Teemu J Murtola, Heimo Syvälä, Pasi Pennanen, Merja Bläuer, Tiina Solakivi, Timo Ylikomi, Teuvo L J Tammela
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39445 (2012)
Cholesterol-lowering treatment has been suggested to delay progression of prostate cancer by decreasing serum LDL. We studied in vitro the effect of extracellular LDL-cholesterol on the number of prostate epithelial cells and on the expression of key
Externí odkaz:
https://doaj.org/article/a8729a04aba042b29caa24e45271cc4e
Autor:
Teemu J. Murtola, Pasi Pennanen, Heimo Syvälä, Timo Ylikomi, Teuvo L.J. Tammela, Kimmo Savinainen, Merja Bläuer
Publikováno v:
European Journal of Pharmacology. 788:160-167
The anti-diabetic drug metformin and cholesterol-lowering statins inhibit prostate cancer cell growth in vitro and have been linked with lowered risk of prostate cancer in epidemiological studies. We evaluated the effects of these drugs on cancerous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95c5e85c5430cc66ec629d4a8eddd95
https://doi.org/10.1016/j.ejphar.2016.06.036
https://doi.org/10.1016/j.ejphar.2016.06.036
Autor:
Reetta Nätkin, Niina H. Ikonen, Teuvo L.J. Tammela, Paavo Raittinen, Pasi Pennanen, Teemu T. Murtola, Matti Nykter, Pauliina Ilmonen, Heimo Syvälä, Merja Bläuer
Publikováno v:
Cancer Research. 80:5913-5913
Metastatic prostate cancer is non-curable fatal disease requiring active treatment. Prostate cancer cell proliferation requires androgen hormones mediated by androgen receptor (AR). Typical metastatic prostate cancer treatment exploits this dependenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3b08cd6ee9779fcb6ec6bcfa696a974
https://doi.org/10.1158/1538-7445.am2020-5913
https://doi.org/10.1158/1538-7445.am2020-5913
Publikováno v:
Biochemical and biophysical research communications. 481(1-2)
We evaluated the effects of simvastatin and antiandrogen enzalutamide on growth and androgen signaling in androgen-sensitive LNCaP and VCaP prostate cancer cells. Simvastatin alone abolished androgen-induced growth in both cell lines but decreased an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e7fa597a4f5adee0174e630bbb2a0c
https://pubmed.ncbi.nlm.nih.gov/27833018
https://pubmed.ncbi.nlm.nih.gov/27833018
Publikováno v:
Steroids. 76:1063-1068
Elevated activator protein-1 (AP-1) activity in breast cancer cells has been linked to Tamoxifen (TAM) resistance. Fos-like antigen-1 (FOSL1) is a member of the AP-1 transcription factor and is overexpressed in a variety of human cancers including br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265d7bb1d0a3c38a903eebe08b892458
https://doi.org/10.1016/j.steroids.2011.04.011
https://doi.org/10.1016/j.steroids.2011.04.011
Publikováno v:
European Journal of Biochemistry. 269:2485-2490
A differential display method was used to study genes the expression of which is altered during growth inhibition induced by medroxyprogesterone acetate (MPA). A transcript of G-protein-coupled receptor 30 (GPR30) was upregulated by MPA in estrogen-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96efe6c6d65742b6a548eb0435011727
https://doi.org/10.1046/j.1432-1033.2002.02912.x
https://doi.org/10.1046/j.1432-1033.2002.02912.x
Autor:
Pekka Vilja, Yan-Ru Lou, T Hasan, Susanna Miettinen, Timo Ylikomi, Pasi Pennanen, N Aksenov, P Pasanen, Pentti Tuohimaa, Merja Bläuer, Heimo Syvälä, Alex Lyakhovich, Tommi Manninen, Merja H. Ahonen
Publikováno v:
University of Helsinki
Our recent epidemiological study (Ahonen et al., Cancer Causes Control 11(2000) (847-852)) suggests that vitamin D deficiency may increase the risk of initiation and progression of prostate cancer. The nested case-control study was based on a 13-year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c24f2f2bdd62946016ea2f40494f8987
https://doi.org/10.1016/s0960-0760(00)00141-2
https://doi.org/10.1016/s0960-0760(00)00141-2
Autor:
Pasi Pennanen, Heimo Syvälä, Merja Bläuer, Timo Ylikomi, Teemu J. Murtola, Teuvo L.J. Tammela, Tiina Solakivi
Publikováno v:
European journal of pharmacology. 673(1-3)
Epidemiological studies have linked statin use with a decreased risk of advanced prostate cancer and an improved recurrence-free survival after radical therapy. It is unclear, however, whether statins could have direct effects against prostate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6ee8b1808ac1c94c8f63a73561e1bc2
https://pubmed.ncbi.nlm.nih.gov/22040920
https://pubmed.ncbi.nlm.nih.gov/22040920
Autor:
Merja Bläuer, Timo Ylikomi, Teemu J. Murtola, Pasi Pennanen, Heimo Syvälä, Teuvo L.J. Tammela
Publikováno v:
The Prostate. 69(9)
BACKGROUND Non-steroidal anti-inflammatory drugs and cholesterol-lowering statins have been reported to inhibit prostate cancer cell growth suggesting their chemopreventive potential within the prostate. However, the effect has been demonstrated only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e87c1401c2f7e5521b7bf81fed4ee0
https://pubmed.ncbi.nlm.nih.gov/20135759
https://pubmed.ncbi.nlm.nih.gov/20135759